Cumberland (CPIX) Q2 FY26 earnings call

Cumberland Pharmaceuticals completed a transformative divestiture of its commercial business to Apotex Health, receiving $100 million in cash and enabling a strategic pivot to an innovation-focused biopharmaceutical model. The company is now well-capitalized, with cash reserves projected to fund operations for over five years, and is accelerating its clinical pipeline, which includes promising programs for Duchenne Muscular Dystrophy, systemic sclerosis, idiopathic pulmonary fibrosis, and cancer metastasis prevention. The call was a monologue with no Q&A.